readthroughSign in
Nov 12, 2026Quarterly update

Twist Bioscience posts record fiscal 2026 revenue, guides to $550M-$560M for fiscal 2027

Twist reported 22% annual revenue growth and positive fourth-quarter adjusted EBITDA, and forecast about 21% revenue growth at the midpoint for fiscal 2027.

Twist Bioscience Corporation reported financial results for the fourth quarter and full fiscal year 2026, ended September 30, 2026, on November 12, 2026. Full-year revenue reached a record $459.4 million, up 22% from $376.6 million in fiscal 2025, while fourth-quarter revenue hit a record $126.6 million, up about 28% from $99.0 million a year earlier, marking the 15th consecutive quarter of sequential growth.1

Looking ahead, Twist expects full fiscal year 2027 total revenue of roughly $550 million to $560 million, representing about 21% growth year over year at the midpoint, with initial guidance assuming $100 million in revenue from AI drug discovery and sequential growth across both its DNA Synthesis and Protein Solutions and NGS Applications segments.1 For the first quarter of fiscal 2027, the company expects total revenue of approximately $130 million to $132 million, growth of approximately 26% year over year at the midpoint and continued sequential growth.1 The company also guided to gross margin of approximately 52.5% to 53%, positive adjusted EBITDA for the year, and capital expenditures of about $75 million as part of a two-year investment plan, excluding landlord-funded tenant improvements.1

On the business side, Twist said it joined Lilly TuneLab as a provider of antibody characterization services1, expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies1, and launched Twist MRD Express, custom panels designed for a rapid turnaround time of as little as one day.1

On capital, the company raised net proceeds of approximately $425 million through an equity offering and at-the-market sales1 during the year. At fiscal year-end, Twist held approximately $582 million in cash, cash equivalents and short-term investments.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.